印度产的阿斯利康疫苗其有效率低于10%,怀疑是恒河水,南非要求退货。

向问天

日月神教光明左使
VIP
注册
2012-09-04
消息
60,489
荣誉分数
11,000
声望点数
1,273
听到"中国疫苗是唯一选择" 西方国家急了
发信站: BBS 未名空间站 (Tue Feb 23 00:36:31 2021, 美东)

一场全球范围内关于新冠肺炎疫苗的讨论,风向似乎越来越清晰了。

这两天,分别来自东西方媒体的两篇关于中西方疫苗的报道引发关注:

20日上午,香港《南华早报》网站刊出《中国疫苗:对许多国家来说,无关政治,而是唯一的选择》一文;一天后(当地时间21日),美国《华尔街日报》网站刊文《中国部署疫苗扩大全球影响力,而美国正在边缘化》。

两篇文章,尽管措辞有所不同、基调有所不同,但本质上说的都是同一个话题:对比某些西方国家的不作为甚至是拖后腿,随着新冠肺炎疫苗在全球范围内的需求量不断上升,中国疫苗在客观上已经成为越来越多国家的选择。中国新冠疫苗加速成“全球公共产品”,已是不争事实。

中国国内披露的数据也在坐实以上论断,据外交部网站消息,中方向巴基斯坦等53个发展中国家提供疫苗援助,已经和正在向22个国家出口疫苗。中方还决定向“新冠肺炎疫苗实施计划”提供1000万剂疫苗,主要用于发展中国家。

正如《南华早报》网站所说,在许多西方国家争先恐后地为本国人口接种疫苗的情况下,中国、俄罗斯和印度的疫苗生产企业正在加紧向低收入和中等收入国家提供疫苗。“这与西方衰落的说法非常吻合。”报道评价道。

这篇报道里,作者还指出一个更为残酷的真相:让中国和俄罗斯赢得大批量新冠疫苗采购协议的,只有一个原因:中俄能够兑现诺言

这一论断在《华尔街日报》网站的报道中得到进一步印证:为了向全球发展中国家提供大批量新冠疫苗,北京正在抓紧组建一个囊括了飞机、卡车和仓库的冷链运输、供应网络系统。这个供应网络旨在加快冠状病毒疫苗的配送速度,并加深中国在发展中国家的影响力。

《华尔街日报》网站引用公共卫生专家、前比尔及梅琳达·盖茨基金会中国主任叶雷(Ray Yip)的话,对中国这一做法进行了盛赞:“如果一切操作得当,这对中国来说是一个真正的双赢机会。”

“当美国和欧洲把注意力集中在自身时,中国像一个‘穿着闪亮铠甲的骑士’一样冲上前去。”叶雷说。

对比鲜明——而同样的反差也发生在欧洲。美国有线电视新闻网(CNN)日前一篇报道就注意到,就在欧盟炫耀已经订购超过23亿剂各种冠状病毒疫苗时,位于西巴尔干的黑山、波黑等欧洲国家迄今为止一剂新冠肺炎疫苗也没有接种过,而此前欧盟承诺给他们的8500万美元防疫药品,始终遥遥无期。这些国家本都是潜在的欧盟成员,但在疫苗供应中却被无形中排除在外、被忽视、被边缘……这一尴尬局面也导致,上述欧洲国家开始纷纷效仿其邻国塞尔维亚的做法,转而争取中国和俄罗斯疫苗。

在CNN的叙事之中,这显然是又一个中西方地缘政治争夺中的“反转”故事,报道援引专家的话表示:错失为西巴尔干国家提供疫苗良机,意味着欧盟将展现软实力的机会“拱手让给了中国”。

面对此情此景,谁心有不甘,谁暗自着急?

终于,再也坐不住的西方国家近日借慕尼黑安全会议和G7峰会作出承诺:将尽快与发展中国家分享疫苗。

例如,法国总统马克龙就在上周的慕尼黑会议上发出疾呼:建议欧洲和美国尽快向非洲提供疫苗,否则非洲朋友将会从中国、俄罗斯那里购买疫苗。而美国总统拜登也承诺将拿出40亿美元用于促进包括全球疫苗接种等公共服务内容。

但美联社同时道出这一承诺的“现实处境”:由于各国国内面临疫情严重程度、疫苗接种进展复杂局面,这些国家的领导人也承受着不同压力,“因此(他们)并不愿透露到底愿意与发展中国家分享多少疫苗,或者何时分享”。

日本《每日新闻》则进一步指出:G7国家这种“善意”背后,实际是对已经在该领域颇有成绩的中俄的警惕感。

说到底,对这些西方国家来说,一切的出发点和目的,从来只有一个:那就是政治利益。这也难怪他们会如此政治化解读中国疫苗了。

这也是所谓夏虫不可语冰,燕雀安知鸿鹄吧。

一切正如在接受《南华早报》采访时,贝尔格莱德分析师斯特凡·弗拉迪萨夫列夫所说:“这(选择中国疫苗)与地缘政治无关,而是(关乎更为迫切、具体的命题)——不丢掉性命,能正常上班,恢复经济运转。”
 

向问天

日月神教光明左使
VIP
注册
2012-09-04
消息
60,489
荣誉分数
11,000
声望点数
1,273
最后编辑:

向问天

日月神教光明左使
VIP
注册
2012-09-04
消息
60,489
荣誉分数
11,000
声望点数
1,273

Canada to receive 2 million doses of AstraZeneca’s COVID-19 vaccine manufactured by the Serum Institute of India​

From: Public Services and Procurement Canada

News release​

February 26 2021 - Gatineau, Quebec - Public Services and Procurement Canada
The Government of Canada is taking steps to ensure more people in Canada are vaccinated more quickly, and continues to work to give Canadians access to safe and effective COVID-19 vaccines as soon as possible.
Following Health Canada’s authorization of the AstraZeneca ChAdOx1 COVID-19 vaccine, the Honourable Anita Anand, Minister of Public Services and Procurement, announced today that Canada has secured 2 million doses of the AstraZeneca COVID-19 vaccine through an agreement with Verity Pharmaceuticals Canada Inc./Serum Institute of India.
AstraZeneca has licensed the manufacture of its ChAdOx1 vaccine to the Serum Institute. The first 500,000 doses will be delivered to Canada in the coming weeks and will quickly be ready for distribution to the provinces and territories. The remaining 1.5 million doses will arrive by mid-May.
The 2 million doses secured through this agreement are in addition to the 20 million doses already secured through an earlier agreement with AstraZeneca. Health Canada’s authorization of the AstraZeneca vaccine allows the Government of Canada to advance its work with AstraZeneca to finalize delivery schedules for the 20 million doses.
This announcement further solidifies Canada’s plan to be able to provide a vaccine to everyone in Canada for whom these COVID-19 vaccines are recommended, by the end of September.

Quotes​

“The Government of Canada continues to do everything possible to protect Canadians from COVID-19. This includes securing a highly diverse and extensive portfolio of vaccines and taking all necessary measures to ready the country to receive them. We remain fully on track to ensure that there will be a sufficient supply so that every eligible Canadian who wants a vaccine will have access to one by the end of September. I am grateful for the collaboration of our partners in India to finalize this agreement, and I look forward to continuing to work closely together in the weeks ahead.”
The Honourable Anita Anand
Minister of Public Services and Procurement

Quick facts​

  • AstraZeneca has licensed the manufacture of its ChAdOx1 vaccine to the Serum Institute, which distributes it under the brand name COVISHIELD.
  • The Government of Canada has signed agreements with the following companies to secure access to their COVID-19 vaccines and vaccine candidates:
    • Pfizer, which will supply a minimum of 40 million doses and up to 76 million doses of its messenger RNA (mRNA) vaccine developed with BioNTech, BNT162b2. The Pfizer-BioNTech COVID-19 vaccine was approved by Health Canada on December 9, 2020. Canada will receive 4 million doses of the Pfizer-BioNTech COVID-19 vaccine before the end of March, and more than 1.5 million doses in the first half of April.
    • Moderna, which will supply 44 million doses of its mRNA vaccine, mRNA-1273. The Moderna COVID-19 vaccine was approved on December 23, 2020. During the week of March 8, Canada is expecting more than 460,000 doses of the Moderna vaccine, and another 846,000 during the week of March 22. These deliveries mean we will have received over 2 million doses in the first quarter.
    • AstraZeneca, which will supply 20 million doses of its viral vector vaccine, ChAdOx1. The AstraZeneca COVID-19 vaccine was approved on February 26, 2021.
    • Verity Pharmaceuticals Canada Inc./Serum Institute of India (in collaboration with AstraZeneca Canada Inc.), which will supply 2 million doses of the ChAdOx1 viral vector vaccine. The Verity Pharmaceuticals Canada Inc./Serum Institute of India (in collaboration with AstraZeneca Canada Inc.) COVID-19 vaccine was approved on February 26, 2021.
    • Medicago, which will supply up to 76 million doses of its virus-like particle vaccine candidate.
    • Sanofi and GlaxoSmithKline, which will supply up to 72 million doses of their protein subunit vaccine candidate.
    • Johnson & Johnson, which will supply up to 38 million doses of its viral vector vaccine candidate, Ad26.COV2.S.
    • Novavax, which will supply up to 76 million doses of its protein subunit vaccine candidate, NVX-CoV2373.
  • The authorization of AstraZeneca’s COVID-19 vaccine also allows the Government of Canada to access its allocation of doses from the COVAX facility.
 

Ottawa005

知名会员
注册
2009-09-03
消息
667
荣誉分数
300
声望点数
173

加大卫生部宣布
又批准了两种新的COVID-19疫苗
分别是阿斯利康疫苗
和印度血清研究所疫苗


Health Canada also has authorized the vaccine manufactured by the Serum Institute, which has partnered with AstraZeneca to make that company's COVID-19 product at its facilities in India. That version, which is biologically identical to the AstraZeneca shot but is manufactured under different conditions, has been branded "Covishield."
 

向问天

日月神教光明左使
VIP
注册
2012-09-04
消息
60,489
荣誉分数
11,000
声望点数
1,273
我是绝对不会打印度生产的疫苗。
 

阿土仔

本站元老
VIP
注册
2007-01-19
消息
18,764
荣誉分数
6,165
声望点数
373

加大卫生部宣布
又批准了两种新的COVID-19疫苗
分别是阿斯利康疫苗
和印度血清研究所疫苗


Health Canada also has authorized the vaccine manufactured by the Serum Institute, which has partnered with AstraZeneca to make that company's COVID-19 product at its facilities in India. That version, which is biologically identical to the AstraZeneca shot but is manufactured under different conditions, has been branded "Covishield."
严重质疑加拿大卫生部,抵制阿斯利康!:mad:
 
最后编辑:

Ottawa005

知名会员
注册
2009-09-03
消息
667
荣誉分数
300
声望点数
173
严重质疑加拿大卫生部,抵制阿斯利康!:mad:

阿斯利康在南非已被叫停,被换成了强生疫苗。
在德国被嫌弃。
在美国也还没获批吧。
实验数据也不十分好。
一样是打两针。
副作用不比别的疫苗小。
还是印度产的。

YouTube 里看的,台湾那边人们也不想打阿斯利康,都在想等下一批的 Moderna
 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
23,311
荣誉分数
5,581
声望点数
373
阿斯利康在南非已被叫停,被换成了强生疫苗。
在德国被嫌弃。
在美国也还没获批吧。
实验数据也不十分好。
一样是打两针。
副作用不比别的疫苗小。
还是印度产的。

YouTube 里看的,台湾那边人们也不想打阿斯利康,都在想等下一批的 Moderna
加拿大进了一大批阿斯利康,也只能买得到这个。
 
顶部